Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: Marc Kahn who wrote (379)	3/16/1999 10:08:00 AM
From: geewiz	Read Replies (1) \| Respond to of 534

Hi gang, Good news on a subject we've all been following; Bioject Initiates Human Clinical Trials Delivering DNA-Based Vaccines for The Treatment of Lymphoma PORTLAND, Ore., March 16 /PRNewswire/ -- Bioject Medical Technologies Inc. (Nasdaq: BJCT - news), the leading manufacturer of jet injection devices for needle-free drug delivery and developer of a continuous ambulatory blood glucose monitoring system, today announced that phase I human trials have begun with Vaxid, a DNA-based vaccine for the treatment of lymphoma using the Biojector 2000® jet injector as a delivery system. The study, sponsored by Vical Incorporated (Nasdaq: VICL - news), is being conducted at the Stanford University Medical Center under the direction of Dr. John Timmerman and Dr. Ronald Levy, the primary investigators. The Biojector 2000® is being used in comparison with needle and syringe because other studies suggest that the Biojector 2000® may be a more optimal route of delivery for DNA-based vaccines. biz.yahoo.com hope this is the start of several vaccines! best, art